"May Contain" Labels on Snacks: How Families Can Actually Decide

The Line That Stops Your Cart

Here's the frustrating truth behind that warning: it is called precautionary allergen labeling (PAL), and in the United States it is entirely voluntary. Federal law — FALCPA (2004), extended by the FASTER Act (2021) — requires manufacturers to declare the nine major allergens (milk, eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, soybeans, and sesame) only when they are intentionally used as ingredients. Unintended cross-contact from shared equipment sits outside that mandate. The FDA asks only that precautionary statements be truthful and not misleading; it sets no threshold, no standard wording, and no requirement to test.

The result is wide inconsistency. A cautious manufacturer may label broadly "just in case"; another with excellent controls may not label at all. "May contain," "made on shared equipment," and "made in a facility that also processes" carry no legally defined difference. Some families avoid every warned product; others call the company each time. The right answer genuinely differs from child to child — which is why this article aims at informed family decisions rather than a blanket rule.

What the Research Shows Is Actually Inside

If the warning is voluntary and unstandardized, what is really in those packages? A European multi-site study by Blom and colleagues (Allergy, 2019, doi.org/10.1111/all.13733) measured allergen levels in over 500 products carrying precautionary labels. The findings cut both ways:

In other words, a may-contain label is neither proof of danger nor proof of safety. Most labeled products carry little or no allergen; a few carry clinically meaningful amounts, and nothing on the package tells you which is which. That uncertainty is exactly why severity-based judgment — not the label alone — has to drive the decision.

VITAL 2.0: The International Yardstick

Australia and New Zealand tackled this inconsistency with VITAL (Voluntary Incidental Trace Allergen Labeling), a framework built by allergy researchers and the food industry together. VITAL sets a reference dose for each allergen — an amount below which an estimated 95-99% of allergic individuals will not react — and recommends a precautionary label only when measured cross-contact exceeds it. The VITAL 2.0 doses were published by Allen and colleagues (Food and Chemical Toxicology, 2014, doi.org/10.1016/j.fct.2014.07.045), expressed as total protein:

• Peanut: 0.2 mg
• Egg: 0.2 mg
• Milk: 0.1 mg
• Wheat (gluten): 1 mg
• Soy: 1 mg

VITAL is not US law, but global manufacturers increasingly reference it internally, and the Codex Alimentarius Commission has been building on it toward international guidance. For families, a product marked as following VITAL-style quantitative assessment is simply easier to reason about than an unexplained "may contain."

One caution: reference doses protect most allergic individuals, not all. A child with prior anaphylaxis, a very low reaction threshold, or ongoing treatment may react below these amounts. The final call always belongs with your child's allergist.

What Manufacturers Actually Do on Shared Lines

Behind identical warnings sit very different factories. Knowing the main cross-contact controls makes manufacturer hotline calls far more productive:

The Blom study found that manufacturers combining three or more of these controls kept measured contamination consistently below VITAL reference doses. Conversely, if a company cannot describe any specific controls when asked, families of severely allergic children are on solid ground treating that product as off the list. Our allergy-friendly snack guide covers brands and homemade routes that sidestep the question entirely.

A Severity-Based Decision Framework

A single yes/no rule for all may-contain products isn't realistic. What works is a layered framework, agreed with your allergist:

1. Layer A — highest caution: history of anaphylaxis, very high specific IgE, or currently in oral immunotherapy. Precautionary-labeled products are avoided as the default. Exceptions only for products with documented controls (VITAL-style assessment, swab-verified cleaning) and explicit allergist sign-off, starting with small amounts. Notably, the PALISADE peanut OIT trial (New England Journal of Medicine, 2018, doi.org/10.1056/NEJMoa1812856) instructed participants to avoid may-contain products for the entire study, because trace exposure can destabilize treatment — directly relevant if your child is in OIT.
2. Layer B — moderate: past reactions at the hives-or-vomiting level, moderate IgE. Case-by-case decisions weighing the manufacturer's controls and the child's current condition. First trials happen at home, during clinic hours, in small amounts.
3. Layer C — lower risk: mild or outgrown reactions confirmed by oral food challenge, or simple oral allergy syndrome. May-contain products are generally workable, with situational caution — skip them on sick days and before intense exercise.
4. All layers: recheck labels periodically. Recipes, suppliers, and factories change, so a product that was fine last year may carry different cross-contact risk today.

Age by Age: Who Reads the Label

• Infants and toddlers (0-2): most foods are still first exposures. Follow the early-introduction guidance your pediatrician uses — the NIAID addendum guidelines (Pediatrics, 2017, doi.org/10.1542/peds.2016-4006) recommend introducing new foods in small amounts, earlier in the day, when medical help is reachable. Lean on home-prepared snacks and keep packaged may-contain products to a minimum.
• Preschoolers (3-5): the "I want THAT one" era. Start narrating the rule out loud — "let's check the small print together before we decide" — so label-reading becomes a shared habit rather than a mysterious veto. Coordinate closely with daycare, where shared snacks appear constantly.
• School-age (6+): friends' houses, birthday parties, team snacks. The rule to hand the child: "a snack with a may-contain warning gets checked at home with us before you ever eat it." By upper elementary, many kids can carry their own chef card and know their travel routine for field trips and camps.

Research on family allergy management by Sicherer and colleagues (Pediatric Allergy and Immunology, 2020, doi.org/10.1111/pai.13208) supports this gradual handover: children who participate in their own management report better quality of life than those managed entirely around them.

Seven Questions to Bring to the Allergist

Clinic time is short. Bringing a prepared list turns a vague worry into a written family policy:

1. Which layer (A/B/C) does my child fit today, and is that likely to change in the next few months?
2. For products with precautionary labels for their allergen: avoid entirely, decide case by case, or eat normally?
3. Does objective manufacturer evidence — VITAL-style assessment, swab-verified cleaning — change your answer?
4. Based on the last oral food challenge, what safety margin do we realistically have?
5. Are there times to be extra careful — sick days, before or after exercise, after vaccinations?
6. What's the recommended procedure for trying a new product (time of day, amount, what to record)?
7. What's our policy for special settings — field trips, overnight camps, international travel?

Write the answers into a shared family note and your child's Food Allergy and Anaphylaxis Emergency Care Plan. When grandparents, sitters, and teachers can all read the same allergist-approved policy, the daily decisions stop being renegotiated from scratch. If several allergens are in play at once, our multi-allergen snack guide maps the safe-swap landscape.

Three Mindsets That Keep This Sustainable

1. The label is a starting point, not a verdict. PAL is the manufacturer's best-effort risk communication under a voluntary system; the decision itself belongs to your family and your allergist.
2. Children change. Thresholds, treatment stages, and maturity all move year by year. This year's rule is not necessarily next year's — build in periodic review.
3. "Skip it to be safe" is a legitimate choice. So is a carefully reasoned yes. Factor in your family's daily bandwidth and your child's emotional load, and build a policy you can actually live with.

Frequently Asked Questions

Are may-contain warnings required by law?

No. FALCPA and the FASTER Act require declaring the nine major allergens only when intentionally used as ingredients. Precautionary statements are voluntary, unstandardized, and threshold-free under current FDA rules.

Does the label mean my child can't eat it?

Not automatically. In the Blom (2019) measurements, about 63% of labeled products had no detectable allergen and only a small share exceeded VITAL reference doses. Decide per product, per child, with your allergist.

Should a child with anaphylaxis history avoid these products?

Default avoidance is the standard conservative approach for anaphylaxis history, very high IgE, or active OIT — the PALISADE trial itself required it. Exceptions need documented manufacturer controls plus allergist sign-off.

Is "same line" worse than "same facility"?

Directionally yes — shared-line wording implies closer contact — but US wording is unstandardized, so never rank risk by phrasing alone. Use ingredient list + manufacturer inquiry + allergist guidance as the three-part check.

How do we handle school and camps?

Only home-proven, allergist-approved products go to school. Put the may-contain policy in writing in the Emergency Care Plan (and 504 plan where applicable) so every adult applies the same rule, and settle field-trip policy in advance.

References and Further Reading

• Allen KJ, Remington BC, Baumert JL, et al. "Allergen reference doses for precautionary labeling (VITAL 2.0): clinical implications." Food and Chemical Toxicology, 2014. doi.org/10.1016/j.fct.2014.07.045
• Blom WM, Michelsen-Huisman AD, van Os-Medendorp H, et al. "Accidental food allergy reactions: products and undeclared allergens." Allergy, 2019. doi.org/10.1111/all.13733
• PALISADE Group of Clinical Investigators. "AR101 oral immunotherapy for peanut allergy." New England Journal of Medicine, 2018. doi.org/10.1056/NEJMoa1812856
• Sicherer SH, et al. "Quality of life and family management in food allergy." Pediatric Allergy and Immunology, 2020. doi.org/10.1111/pai.13208
• Togias A, Cooper SF, Acebal ML, et al. "Addendum guidelines for the prevention of peanut allergy in the United States." Pediatrics, 2017. doi.org/10.1542/peds.2016-4006